Financial Relationships With Ineligible Companies

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as "commercial interests") within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." Below are the financial interests that faculty members of this course have had within the past 24 months. View the Faculty Financial Disclosure Policy on the IAS–USA website.

Beyond ART: Hot Topics in HIV Primary Care

November 16, 2026

Course Presenters and Panelists	
Rebecca A. Abelman, MD Assistant Professor University of California San Francisco San Francisco, CA	Dr Abelman reported receiving grants paid to her institution from Merck & Co, Inc. (Updated November 10, 2025)
Kristine M. Erlandson, MD, MS Professor of Medicine University of Colorado Aurora, CO	Dr Erlandson reported receiving noncash provisions of medicines, equipment, or administrative support with Theratechnologies, Inc, and serving on data monitoring boards with Merck & Co, Inc, ViiV Healthcare, and Gilead Sciences, Inc. (Updated June 8, 2026)
David Grelotti, MD Clinical Professor of Psychiatry University of California San Diego San Diego, CA	Dr Grelotti reported no relevant financial relationships with ineligible companies. (Updated June 11, 2026)
Joshua P. Havens, PharmD Associate Clinical Professor University of Nebraska Medical Center Omaha, NE	Dr Havens reported serving as a consultant to Merck & Co, Inc, and ViiV Healthcare, and receiving grants paid to his institution from Gilead Sciences, Inc. (Updated May 29, 2026)
Suman Srinivasa, MD, MS Assistant Professor of Medicine Harvard Medical School Boston, MA	Dr Srinivasa reported serving as a consultant to Parabilis Medicines. (Updated June 5, 2026)
Christina M. Wyatt, MD Associate Professor of Medicine Duke University Durham, NC	Dr Wyatt reported serving as a consultant to Novo Nordisk. (Updated June 11, 2026)

IAS–USA CME Planners and Reviewers	
Darcy A. Wooten, MD Professor of Medicine Washington University St Louis, MO	Dr Wooten reported no relevant financial relationships with ineligible companies. (Updated November 5, 2025)
Melanie A. Thompson, MD Physician Thacker & Thompson, MD Atlanta, GA	Dr Thompson reported serving on data monitoring boards with Excision BioTherapeutics, Inc. (Updated May 1, 2026)
Donna M. Jacobsen Executive Director/President IAS–USA San Francisco, CA	Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated July 15, 2026)

IAS–USA Boards
The nonstaff members of the IAS–USA Scientific Advisory Board and Governance Board are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.